Febrile Neutropenia/Immunocompromised Host Consult Note

Date/Time: [Encounter date and time] | Note completed: [Note completion time]

Consulting Service: [Infectious Diseases / Transplant ID / Oncology ID] ([Attending / Fellow / Advanced Practice Provider])

Location: [ED / Inpatient / ICU]

Requesting Service: [Service name and clinician] via [page / phone / secure message]

Reason for Consult: [Single-sentence clinical question focused on febrile neutropenia or fever in immunocompromised host]

Executive Summary

[Age]-year-old [sex] with [primary immunocompromising condition and phase] presenting with fever. ANC [value] ([increasing / stable / decreasing]; [brief ≤7 days / prolonged >7 days] duration expected). Fever onset [date/time], Tmax [value]. Hemodynamically [stable / unstable] with [lowest BP or MAP], [oxygen requirement]. On [empiric antimicrobials with doses] started at [time], [before / after] cultures. [Central line type and site / No central venous access]. [Key focal findings / No localizing symptoms].

History of Present Illness

Fever and sepsis timeline: [Time of first fever]; [temperature trajectory with values and times]; [time antibiotics started relative to culture collection]; [hemodynamic events: hypotension, lactate, vasopressors]; [oxygen requirements]; [rigors or chills with line infusions: present / absent].

Neutropenia characterization: [Etiology: chemotherapy / HSCT / medication / marrow failure]; ANC nadir [value, date]; current ANC [value]; trend [increasing / stable / decreasing]; [profound ≤100 / not profound]; expected duration [≤7 days / >7 days] based on [rationale].

Immunosuppression context: [Malignancy type, remission status, current regimen and cycle/day]; [HSCT: auto/allo, day post-transplant, engraftment status, GVHD, immunosuppressants]; [SOT: organ, time since transplant, rejection history, immunosuppression]; [Cellular therapy: product, day post-infusion, complications]; [Steroids: dose in mg prednisone equivalent, duration]; [High-risk agents: purine analogs, anti-CD20, calcineurin/mTOR inhibitors, JAK inhibitors]. (Include only applicable categories.)

Symptoms and source clues: [Respiratory]; [GI]; [GU]; [Skin/line sites]; [Neuro]; [Sinus]; [Perirectal]. (Document pertinent negatives that meaningfully alter risk; state "no localizing symptoms" if none identified.)

Infection and colonization history: [Prior bloodstream infections with organisms, resistance, dates]; [Colonization: MRSA / VRE / ESBL / CRE / MDR Pseudomonas with dates]; [C. difficile history]; [Hospitalizations and antibiotics within 90 days]; [Prior invasive fungal disease]; [Viral reactivations: CMV, EBV]. (If unknown, state explicitly and note plan to verify.)

Medication allergies: [Agent, reaction type, severity, timing]. (Distinguish IgE-mediated vs intolerance vs severe cutaneous reactions; document beta-lactam details specifically.)

Prophylaxis History

• Antibacterial: [Agent, dose/schedule, last confirmed dose]
• Antifungal: [Agent]; [yeast-active / mold-active]; [drug level and date if applicable]
• Antiviral: [HSV/VZV agent]; CMV strategy [prophylaxis / preemptive monitoring]; [last PCR if available]
• PJP prophylaxis: [Agent and schedule]; [any intolerance]
• HBV prophylaxis: [Agent if applicable]

(If prophylaxis status unknown, state explicitly and note plan to verify with pharmacy/chart.)

Risk Stratification

Risk category: [High-risk / Low-risk] febrile neutropenia.

Rationale: [Anticipated neutropenia duration and depth]; [hemodynamic status]; [pneumonia: present / absent]; [abdominal or neurologic symptoms: present / absent]; [organ dysfunction]; [significant comorbidities].

Validated score: [MASCC score: components and total] or [CISNE score for stable solid tumor patients: components and total]. (Include only if applicable and calculable.)

Outpatient management considerations: [Oral intake adequate]; [vital signs stable]; [reliable follow-up access]; [caregiver available]. (Include only if outpatient therapy is being considered.)

Objective Data

Vitals (current | worst 24h): T [current] | Tmax [value, time]; HR [current] | max [value]; BP [current] | lowest [value], MAP [value]; RR [current]; SpO2 [current]% on [room air / device and FiO2] | highest O2 requirement [value]; mental status [descriptor].

Physical exam: General: [appearance]. Oropharynx: [mucositis grade if present]. Skin: [findings]. Catheter site: [inspection of insertion and tunnel]. Lungs: [findings]. CV: [findings]. Abdomen: [tenderness, distension]. Perineum: [inspection findings; avoid DRE in severe neutropenia]. Neuro: [findings]. (Note exam limitations if applicable.)

Labs with trends: WBC [value], ANC [value] ([trend from prior values]); Hgb [value], Plt [value]; Cr [value] (baseline [value]); hepatic function [AST/ALT/Tbili]; lactate [value, time] if obtained; [other pertinent labs].

Microbiology:

• Blood cultures: [Number of sets, sources (peripheral, each lumen), date/time drawn, results, time-to-positivity if available]
• Urine culture: [Collection method, date/time, result]
• Respiratory: [PCR panels, sputum/BAL cultures, results]
• Stool: [C. difficile, GI pathogen panel] (if applicable)
• Prior relevant microbiology: [Organisms and resistance patterns informing current coverage]

Imaging: [Study, date, key findings]. (Note if imaging indicated but pending.)

Assessment

[Syndrome: febrile neutropenia / fever in profoundly immunocompromised host]; [Severity: uncomplicated / sepsis / septic shock]; [pulmonary involvement / abdominal concern if present]; [Infection category: fever of unknown origin / microbiologically documented / clinically documented].

Differential diagnosis:

• Bacterial: [Gram-negative including Pseudomonas; Gram-positive including catheter-related] — [supporting/refuting features]
• Fungal: [Candida vs invasive mold based on prophylaxis and neutropenia duration] — [supporting/refuting features]
• Viral: [Respiratory viruses; HSV/VZV; CMV/EBV reactivation] — [supporting/refuting features]
• Opportunistic: [PJP, Nocardia, other] — [supporting/refuting features] (if applicable to host)
• Noninfectious: [Drug fever; transfusion reaction; thrombosis; tumor fever; cytokine release] — [supporting/refuting features]

Recommendations

Empiric Antibacterial Therapy

• Current regimen: [Agent(s), dose, route, frequency, start time]; [renal/hepatic adjustments applied]
• Rationale: [Antipseudomonal coverage; local resistance patterns; prior colonization; allergy constraints]
• Actions: [Continue / Start / Stop] [agent] — [reason]
• MRSA/gram-positive coverage: [Indicated now: catheter tunnel infection / pneumonia / SSTI / hemodynamic instability] or [Not indicated: no clinical syndrome, hemodynamically stable]
• Criteria to add coverage: [Specify triggers: new hypotension, worsening respiratory status, positive cultures, etc.]

Site-Specific Infections

(Include only for documented or strongly suspected foci; omit section if none identified.)

[Catheter-related / Pneumonia / Neutropenic enterocolitis / Skin-soft tissue / C. difficile / Sinusitis / Perirectal / Other]:

• Working diagnosis: [Diagnosis] based on [key supporting features]
• Diagnostics: [Tests ordered with timing]
• Therapy: [Targeted antimicrobial changes; duration; source control measures]

Antifungal Strategy

• Invasive mold risk: [High / Intermediate / Low] based on [neutropenia duration, immune phase, prophylaxis status, prior mold infection]
• Current prophylaxis: [Mold-active / Yeast-active / None]; adherence [confirmed / uncertain]
• Diagnostic plan: [Galactomannan, beta-D-glucan, CT chest, sinus CT, bronchoscopy] with timing
• Therapeutic approach: [Empiric / Preemptive] strategy; triggers to start mold-active therapy: [persistent fever beyond specified timeframe, suggestive imaging, positive biomarkers]
• Drug interactions: [Azole interactions with calcineurin/mTOR inhibitors; dose adjustments; TDM plan]

Antiviral and Opportunistic Infection Considerations

• HSV/VZV: [Symptoms]; [prophylaxis adequate: yes / no]; [testing if indicated]
• CMV/EBV: [Risk level]; [monitoring strategy]; [recent PCR results]; [treatment threshold]
• Respiratory viruses: [Testing ordered]; [isolation precautions]; [treatment if positive]
• PJP: [Prophylaxis status]; [clinical suspicion]; [diagnostics: LDH, CT, PCR]; [therapy if indicated]

Persistent Fever Pathway

• Threshold: Persistent fever defined as [duration, typically 48-72 hours] on appropriate therapy
• Re-evaluation: [Repeat cultures if indicated; CT chest/sinuses/abdomen for high-risk without source; invasive diagnostics criteria]
• Stewardship principle: Avoid empiric broadening in stable patients without new data; changes should be data-driven

De-escalation and Duration Criteria

• 48-72 hour timeout: Review culture results, clinical trajectory, imaging, ANC trend
• Gram-positive stop rule: Discontinue at [48-72 hours] if cultures negative and no gram-positive syndrome
• Narrowing: Adjust to organism and susceptibility-directed therapy when identified
• IV-to-PO criteria: Afebrile ≥[duration]; hemodynamically stable; GI absorption reliable; no uncontrolled focus; follow-up arranged
• FUO stopping strategy: [ANC-based continuation / Early stop if stable and afebrile] — rationale: [patient-specific factors]; restart plan if fever recurs: [specify]

Medication Safety

• Renal dosing: [Adjustments made; monitoring frequency]
• QTc risk: [Assessment; EKG plan if multiple QT-prolonging agents]
• Drug interactions: [Key interactions identified; management plan]
• TDM: [Agent, target range, timing of levels]

Communication and Follow-up

• Communicated to: [Name/role] at [time] via [method]
• Follow-up: [Daily ID rounding / As-needed with triggers: hemodynamic change, positive cultures, respiratory decline, persistent fever, new focal findings]
• Escalation criteria: [ICU evaluation triggers; indications to broaden coverage; urgent source control indications]
• Pending studies: [List with expected result times]
• Information to verify: [Specific unknowns and plan to obtain]